Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...
At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 ...
Crinetics Pharmaceuticals stock is a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for ...
On Sunday at the Endocrine Society's Annual Meeting in Chicago, Danish biopharmaceutical company H. Lundbeck presented a result that endocrinologists tracking Cushing's disease drug development have ...
H. Lundbeck A/S (Lundbeck) today announced preliminary Phase II Part A data from its ongoing study evaluating asedebart (Lu AG13909), an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in ...
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results